Addex Therapeutics Files 2024 Annual Report

Ticker: ADXN · Form: 20-F · Filed: May 15, 2025 · CIK: 1574232

Sentiment: neutral

Topics: annual-report, pharmaceuticals, sec-filing

TL;DR

Addex Therapeutics filed its 2024 20-F, check it for the latest financials and biz ops.

AI Summary

Addex Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in V8 and headquartered in Geneva, Switzerland, operates in the pharmaceutical preparations sector. Key financial data and operational details for the period are presented in this filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Addex Therapeutics' financial performance and business operations for the fiscal year 2024, crucial for assessing the company's health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Addex Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition, which are detailed within the 20-F filing.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Addex Therapeutics Ltd. as indicated by its SIC code?

The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

What is the fiscal year end date for the reported period?

The fiscal year end date is December 31, 2024.

Where is Addex Therapeutics Ltd. headquartered?

The company's business and mailing address is in GENEVA, Switzerland.

What is the SEC file number for Addex Therapeutics Ltd.?

The SEC file number is 001-39179.

What is the Central Index Key (CIK) for Addex Therapeutics Ltd.?

The Central Index Key for Addex Therapeutics Ltd. is 0001574232.

Filing Details

This Form 20-F (Form 20-F) was filed with the SEC on May 15, 2025 regarding Addex Therapeutics Ltd. (ADXN).

View full filing on EDGAR

View Full Filing

View this 20-F filing on SEC EDGAR

View on Read The Filing